Introduction
============

Ischemic heart disease (IHD) is a major threat to human health, which increases the burden on the heart muscle ([@b1-mmr-18-01-0193]). It is estimated that \>7 million succumbed to heart diseases in 2010 ([@b2-mmr-18-01-0193]). Cardiac hypertrophy is a critical phenotype that occurs in response to long-term cardiac overload ([@b3-mmr-18-01-0193],[@b4-mmr-18-01-0193]), which is frequently coupled with inflammation, myocardial fibrosis and cell death. The characteristics of cardiac hypertrophy consist of cell surface enlargement, increased protein synthesis and alteration of expression level of associated genes. Therefore, preventing and reversing myocardial hypertrophy has become the main target of cardiovascular disease treatment. Accordingly, it is essential to develop drugs that can protect against myocardial injury.

*Actinidia chinensis* planch contains polyphenolic acid. Its main active compound is *Actinidia chinensis* planch polysaccharide (ACP) ([@b5-mmr-18-01-0193]). ACP exhibits antibacterial, antiviral and anti-tumor effects ([@b6-mmr-18-01-0193],[@b7-mmr-18-01-0193]). However, little is known about the effects of ACP on cardiomyocytes, and the underlying mechanisms have not yet been fully elucidated and require further exploration. In addition, investigating the potential molecular mechanisms will provide important theoretical and practical significance for the treatment of IHD. During the progression of IHD, a number of cellular responses are involved, including gene transcription, protein translation and cellular signal transduction ([@b8-mmr-18-01-0193],[@b9-mmr-18-01-0193]). It has been reported that apoptosis may be the cellular basis for the pathological progression of cardiac hypertrophy, induced by repeated ischemic events, to heart failure ([@b4-mmr-18-01-0193],[@b10-mmr-18-01-0193],[@b11-mmr-18-01-0193]). Currently, there are two main pathways associated with apoptosis, the caspase-dependent and non-caspase-dependent pathways ([@b12-mmr-18-01-0193]). The former includes the death receptor-mediated extrinsic pathway and the intrinsic mitochondrial pathway, which is associated with caspase-8 and caspase-9 ([@b4-mmr-18-01-0193],[@b13-mmr-18-01-0193]). Apoptosis-inducing factor mitochondria associated 1 (AIF) is associated with non-caspase-dependent pathways. It has been demonstrated that caspase-3 serves a pivotal role in the majority of apoptotic processes ([@b14-mmr-18-01-0193]). Furthermore, it is reported that the hypoxic conditions of cardiomyocytes could induce cell apoptosis *in vitro* ([@b15-mmr-18-01-0193],[@b16-mmr-18-01-0193]), which mimic the process of ischemia of myocardial cells in the body. Phosphoinositide 3-kinase (PI3K) is a lipid kinase and the downstream target is serine/threonine kinase protein kinase B (AKT), a conserved signal transduction enzyme. The PI3K/AKT signaling pathway is critical to regulate cellular activation, inflammatory responses and apoptosis ([@b17-mmr-18-01-0193]). In addition, the extracellular signal-regulated kinase (ERK1/2) signaling pathway serves a key role in cell proliferation, survival, transformation and apoptosis ([@b18-mmr-18-01-0193]). It is well known that ERK1/2 and PI3K/AKT can be activated by phosphorylation. The protective effects of the ERK1/2 and PI3K/AKT signaling pathways in cardiomyocytes have been studied extensively ([@b19-mmr-18-01-0193]--[@b21-mmr-18-01-0193]).

In the present study, the protective effect and mechanisms of ACP on the cardiomyocytes of rats was investigated. The results of the present study indicated that ACP could protect against apoptosis induced by hypoxia in cardiomyocytes treated with Angiotensin II (Ang II). The potential mechanisms may be associated with inhibiting the activation of ERK1/2 and PI3K/AKT. The results of the present study provide important information for the theoretical study and clinical treatment of the IHD.

Materials and methods
=====================

### Cell culture and treatment

H9c2 cells were purchased from American Type Culture Collection (Manassas, VA, USA). Purified ACP was acquired from Xian Tianrui Biological Technology Co., Ltd. (Xi\'an, China). Ang II used in this study was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Cells were maintained in Dulbecco\'s modified Eagle media (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (Sangon Biotech Co., Ltd., Shanghai, China), 100 U/ml penicillin and 10 µg/ml streptomycin (Takara Biotechnology Co., Ltd., Dalian, China) in a humid atmosphere of 5% CO~2~ and 95% air at 37°C. Hypoxia treatment was used to mimic myocardial ischemia in the body ([@b22-mmr-18-01-0193]). At \~80% confluence, H9c2 cells were cultured in serum-free medium overnight at 37°C and five treatment groups were applied for the subsequent experiments: i) Normal group, H9c2 cells were cultured with 0.1% DMSO; ii) model group (MG), H9c2 cells were treated with 1 µM Ang II for 48 h; iii) hypoxia treatment group (MGH), H9c2 cells were treated 1 µM Ang II for 48 h, then the cells were incubated at 37°C in a humidified atmosphere containing 95% N~2~ and 5% CO~2~ for 8 h; iv) ACP pretreatment groups, Ang II-treated (1 µM, 48 h) H9c2 cells were incubated in the medium containing ACP at different doses (1.25 and 2.5 mg/ml) for 6 h prior to hypoxia treatment for 8 h. For the specific activation of ERK1/2 and PI3K/AKT, according to previous studies ([@b23-mmr-18-01-0193],[@b24-mmr-18-01-0193]), the cells were treated with recombinant human epidermal growth factor (EGF; 100 ng/ml) and insulin-like growth factor 1 (IGF-I; 100 ng/ml) for 12 h, respectively. Then the cells were subjected to treatment with ACP and hypoxia.

### Cell viability measurement

Cells in a 96-well plate at a density of 1×10^4^ cells per well were serum starved overnight prior to detection and then maintained as described above. Cell viability was analyzed by Cell Counting kit-8 (CCK-8; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) according to the manufacturer\'s protocol. The absorbance at 450 nm was measured on a spectrophotometric plate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Each group was repeated in three different wells.

### Mitochondrial membrane potential (MMP) analysis

Cells in a 96-well plate at a density of 1×10^4^ cell/well were treated as aforementioned. Under normal conditions, the MMP is high and the JC-1 probe exhibits a predominantly red fluorescence. The MMP is reduced in an apoptotic or necrotic state and JC-1 dye fluoresces green. Cells were incubated with the JC-1 (BioVision, Inc., Milpitas, CA, USA) working solution for 20 min at 37°C in the dark. The MMP was detected using a flow cytometer and CellQuest software version 3.3 (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer\'s protocols.

### Measurement of apoptosis

Following treatment as described above, H9c2 cells (2×10^5^/well) in a 6-well plate were stained by Annexin-V and propidium iodide using the fluorescein isothiocyanate (FITC) Annexin-V apoptosis detection kit (Invitrogen; Thermo Fisher Scientific, Inc.) as described previously ([@b25-mmr-18-01-0193]). Then, flow cytometry was carried out using a flow cytometer and CellQuest software version 3.3 (BD Biosciences) according to the manufacturer\'s protocols.

### Leucine incorporation assay

The protein synthesis rate was examined as previously described ([@b26-mmr-18-01-0193]). According to the manufacturer\'s protocols, the incorporation of ^3^H-Leu \[counts per minute CPM)\] was measured by liquid scintillation counter (Perkin Elmer, Inc., Waltham, MA, USA).

### Bradford assay

H9c2 cells were treated as aforementioned. Bradford reagent (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) was added to each sample according to the manufacturer\'s protocol. Then the samples were analyzed to determine their absorbance at 595 nm. A standard curve of bovine serum albumin (BSA; Gibco; Thermo Fisher Scientific, Inc.) was used as a control for all experiments. The protein content was detected by spectrophotometry (Nanodrop; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA).

### Immunofluorescence staining assay

The cells in control, Ang II and ACP+Ang II groups were prepared on slides for the subsequent experiments. The slides were blocked by 5% BSA for 30 min at room temperature prior to the cardiac troponin-T specific monoclonal antibody (cat. no. ab8259; 1:200; Abcam, Cambridge, UK) being added at 4°C, overnight. Then the slides were incubated with the anti-immunoglobulin G/FITC (cat. no. ab150117; 1 µg/ml; Abcam, Cambridge, UK) secondary antibody at room temperature for 1 h; nuclei were stained with DAPI for 15 min at 37°C. The slides were mounted, a coverslip was added and then the slides were observed with a fluorescence microscope (Olympus Corporation, Tokyo, Japan). Then, 4 fields in each group were randomly selected for analysis. The cell surface area was analyzed by Image Pro-Plus software version 6.1 (Media Cybernetics, Inc., Rockville, MD, USA).

### Total RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted with the TRIzol reagent, according to the manufacturer\'s instructions (Life Technologies; Thermo Fisher Scientific, Inc.). The RNA (2 µg) was reverse transcribed using oligo (dT) primer (Takara Biotechnology Co., Ltd.) and the M-MLV reverse transcriptase (Promega Corporation, Madison, WI, USA). The protocol was 65°C for 5 min; 25°C for 10 min; 42°C for 50 min; 70°C for 15 min; and holding at 4°C. The mRNA expression was quantified using ABI 7500 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) and SYBR-Green method ([@b27-mmr-18-01-0193],[@b28-mmr-18-01-0193]) SYBR Premix Taq™ II kit (Takara Bio, Inc., Otsu, Japan) was adopted for the amplification. Relative expression levels were calculated using the 2^−∆∆Cq^ method, according to the previous description ([@b29-mmr-18-01-0193],[@b30-mmr-18-01-0193]). The amplification cycling conditions were as follows: 10 min at 95°C, then 40 cycles of 15 sec at 95°C, 30 sec at 60°C and then a final extension step of 7 min at 72°C. Primer sequences for RT-qPCR were: AIF forward, 5′-CCGGGTAAATGCAGAGCTTC-3′ and reverse, 5′-GCTCTGCATTTACCCGGAAG-3′; caspase-3 forward, 5′-AGAGCTGGACTGCGGTATTGAG-3′ and reverse, 5′-GAACCATGACCCGTCCCTTG-3′; caspase-8 forward, 5′-GAGGAAATGGTGAGGGAGCT-3′ and reverse, 5′-GCTCGAGTTGTCTTGCAGTT-3′; caspase-9 forward, 5′-CATTGGTTCTGGCAGAGCTC-3′ and reverse, 5′-TCAGGTCGTTCTTCACCTCC-3′; GAPDH forward, 5′-GGCACAGTCAAGGCTGAGAATG-3′ and reverse, 5′-ATGGTGGTGAAGACGCCAGTA-3′.

### Western blot analysis

Total proteins were extracted using the Total protein extraction kit (Beijing Solarbio Science & Technology Co., Ltd.). The concentration of proteins was determined by BCA Protein Assay kit (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. Equivalent amounts (15 µg) of protein were separated by 10% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc.). For non-specific blocking, 5% non-fat milk was used. The blots were then incubated with primary antibodies at 4°C overnight. The next day, the blots were incubated with a horseradish peroxidase-conjugated secondary antibody at room temperature for 1 h. Blots were developed using the enhanced chemiluminescence Western Blotting Substrate (Pierce; Thermo Fisher Scientific, Inc.). The antibodies used were anti-cleaved caspase-3 (cat. no. 9664; 1:1,000), anti-cleaved caspase-8 (cat. no. 9496; 1:1,000), anti-cleaved caspase-9 (cat. no. 9505; 1:1,000), anti-AIF (cat. no. 5318; 1:1,000), anti-phosphorylated (p)-ERK1/2 (cat. no. 4370; 1:2,000), anti-p-AKT (cat. no. 4060; 1:2,000), anti-p-PIK3 (cat. no. 4228; 1:1,000), anti-ERK1/2 (cat. no. 4695; 1:1,000), anti-AKT (cat. no. 4685; 1:1,000), anti-PIK3 (cat. no. 3358; 1:1,000) and anti-GAPDH (cat. no. 5174; 1:1,000), all of which were from Cell Signaling Technology, Inc. (Danvers, MA, USA). The horseradish peroxidase-conjugated secondary antibody (cat. no. sc-2004; 1:5,000) was from Santa Cruz Biotechnology, Inc., (Dallas, TX, USA). Signals were visualized using BeyoECL Plus (Beyotime Institute of Biotechnology, Haimen, China). The density of the protein band was quantified with Quantity One Basic software version 4.4.0 (Bio-Rad).

### Statistical analysis

All experiments in the present study were repeated independently ≥3 times. All the data were analyzed using GraphPad software version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) by one-way analysis of variance followed by Tukey\'s multiple comparison test. Data was expressed as the mean ± standard deviation. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Analysis of the cytotoxicity of ACP in cardiomyocytes

To optimize the concentration used in the present study, the cytotoxicity of ACP at different doses on cardiomyocytes was examined, as described by a previous study ([@b31-mmr-18-01-0193]). The CCK-8 assay revealed that cell viability began to be inhibited at 5 mg/ml, although there was no significant difference compared with the control group until 10 mg/ml. Thus, the viability of cardiomyocytes was suppressed by ACP at 10 mg/ml ([Fig. 1](#f1-mmr-18-01-0193){ref-type="fig"}). Therefore, the concentrations of 1.25 and 2.5 mg/ml were used for the subsequent experiments.

### ACP alleviates Ang II induced cardiac hypertrophy

As shown in [Fig. 2A](#f2-mmr-18-01-0193){ref-type="fig"}, the cardiac phenotype of the obtained cells was identified. The surface area of the cell was enlarged in cardiomyocytes stimulated with Ang II, while ACP significantly reduced the cardiac hypertrophy compared with the Ang II treated group (P\<0.01; [Fig. 2A and B](#f2-mmr-18-01-0193){ref-type="fig"}). Additionally, the leucine incorporation assay demonstrated that ACP significantly decreased the elevation in protein synthesis rate induced by treatment with Ang II. (P\<0.05; [Fig. 2C](#f2-mmr-18-01-0193){ref-type="fig"}). In addition, the Bradford assay demonstrated that the protein content was significantly decreased by ACP treatment compared with Ang II alone (P\<0.05; [Fig. 2D](#f2-mmr-18-01-0193){ref-type="fig"}).

### ACP improves the survival of cardiomyocytes

It is known that mitochondrial dysfunction will trigger a cellular crisis ([@b32-mmr-18-01-0193],[@b33-mmr-18-01-0193]). It was demonstrated using flow cytometric analysis that the disruption of the MMP was increased in the MGH group when compared with the model group. The MMP was recovered effectively by pretreatment with ACP ([Fig. 3A and B](#f3-mmr-18-01-0193){ref-type="fig"}). In addition, the CCK-8 assay demonstrated that cell viability was significantly improved in the ACP pretreatment groups compared with the MGH group (P\<0.05; [Fig. 3C](#f3-mmr-18-01-0193){ref-type="fig"}). These results suggested that ACP could improve the survival of cardiomyocytes.

### ACP mitigates apoptosis induced by hypoxia in hypertrophic cardiomyocytes

Disruption of the MMP is recognized as an important event during the early stage of apoptosis ([@b34-mmr-18-01-0193],[@b35-mmr-18-01-0193]). The flow cytometric analysis demonstrated that cell apoptosis was low in the model group whereas it was significantly increased in the MGH group in comparison (P\<0.01; [Fig. 4A and B](#f4-mmr-18-01-0193){ref-type="fig"}). However, cell apoptosis was significantly decreased in the ACP pretreatment groups compared with the MGH group (P\<0.01; [Fig. 4A and B](#f4-mmr-18-01-0193){ref-type="fig"}). Furthermore, the mRNA expression of apoptosis-associated genes including AIF and caspase-3/8/9 were downregulated in the ACP pretreatment groups compared with the MGH group ([Fig. 4C](#f4-mmr-18-01-0193){ref-type="fig"}). Western blot analysis demonstrated the protein levels of AIF and cleaved caspase-3/8/9 were decreased in the ACP pretreatment groups compared with the MGH group ([Fig. 4D and E](#f4-mmr-18-01-0193){ref-type="fig"}).

### ACP inhibits the phosphorylation of ERK1/2 and PI3K/AKT

It has been reported that the ERK1/2 and PI3K/AKT signaling pathways contribute to the maintenance of myocardial morphology and function ([@b36-mmr-18-01-0193]). Western blot analysis indicated that the phosphorylation levels of ERK1/2 and PI3K/AKT were increased in the model group compared to control group; while it was further increased in the MGH groups. The expression of p-ERK1/2, p-PI3K and p-AKT were depressed in the ACP pretreatment groups when compared with the MGH group ([Fig. 5](#f5-mmr-18-01-0193){ref-type="fig"}).

### Specific activation of ERK1/2 and PI3K/AKT reverses the inhibitory effect of ACP on apoptosis

Furthermore, specific activators were used to determine the involvement of ERK1/2 and PI3K/AKT in the protective role of ACP. Recombinant human EGF and IGF-I are activators for ERK1/2 and PI3K/AKT, respectively. Results from flow cytometry analysis demonstrated that the activation of ERK1/2 and PI3K/AKT did not inhibit hypoxia-induced apoptosis even in the presence of ACP ([Fig. 6](#f6-mmr-18-01-0193){ref-type="fig"}). It was suggested that the protective effects of are ACP likely dependent on inhibiting the activation of the ERK1/2 and PI3K/AKT signaling pathways.

Discussion
==========

IHD is a major threat to human health. Cardiac hypertrophy is a common complication during the progression of IHD. It is recognized that apoptosis serves an important role during the progression from cardiac hypertrophy to heart failure ([@b37-mmr-18-01-0193],[@b38-mmr-18-01-0193]). It is hypothesized that cell apoptosis possesses a close connection with the development of the heart diseases. As the center of cellular energy and metabolism, the mitochondria serve a critical role in the progression of cellular apoptosis ([@b39-mmr-18-01-0193]). It has been reported that ACP possesses multiple bioactivities ([@b6-mmr-18-01-0193],[@b7-mmr-18-01-0193]). In the present study, the potential effects of ACP on cardiomyocytes of rats were investigated *in vitro*.

In the present study, Ang II was used to induce cardiac hypertrophy. In addition, pretreatment with ACP reduced cardiac hypertrophy. The collapse of the MMP leads to release of pro-apoptotic molecules into the cytoplasm ([@b40-mmr-18-01-0193]). Pretreatment with ACP rescued the disruption of the MMP and improved the cell viability of cardiomyocytes. It was indicated that the prevention of mitochondrial dysfunction could protect against myocardial injury ([@b41-mmr-18-01-0193]). Furthermore, the rate of apoptosis was decreased in the ACP pretreatment groups compared with the MGH group. Several important molecules are involved in apoptosis signals including AIF ([@b42-mmr-18-01-0193]) and caspases-3/8/9 ([@b43-mmr-18-01-0193]). The results of the present study demonstrated that the expression of AIF and caspase-3/8/9 was downregulated in the ACP pretreatment groups compared with those of the MGH group at the transcriptional and translational levels. These results suggested that ACP could protect against cardiomyocyte apoptosis by regulating the apoptosis-associated genes (AIF and caspase-3/8/9), which is in agreement with the published anti-apoptotic effect of ACP in Neuro-2A cells ([@b39-mmr-18-01-0193]). However, a previous study demonstrated that ACP inhibited growth and induced apoptosis in human gastric cancer cells ([@b31-mmr-18-01-0193]). These results may be attributed to several factors, including the difference in the dosage of ACP, cell types and pathological processes. A previous study demonstrated that the endoplasmic reticulum stress-mediated pathway is involved in apoptosis ([@b44-mmr-18-01-0193]). However, the role of endoplasmic reticulum-mediated apoptosis in the present study model is not clear. Additionally, it is known that the ERK1/2 and PI3K/AKT signaling pathways are involved in cardio-protection ([@b45-mmr-18-01-0193],[@b46-mmr-18-01-0193]). Notably, the results of the present study demonstrated that pretreatment with ACP inhibited the expression of p-ERK1/2 and p-PI3K/AKT. In addition, the activation of ERK1/2 and PI3K/AKT reversed the inhibitory effect of ACP on apoptosis. It is possible that ACP inhibited the phosphorylation of ERK1/2 and PI3K/AKT thereby decreasing myocardial apoptosis induced by hypoxia. However, it was reported that ERK1/2 and PI3K/AKT were activated in multiple types of cancer, promoting cell survival and inhibiting apoptosis ([@b47-mmr-18-01-0193]--[@b49-mmr-18-01-0193]). Nevertheless, previous studies have demonstrated that instead of inhibiting cell death, the sustained activation of ERK1/2 and PI3K/AKT rendered cells more sensitive to metabolic stress ([@b50-mmr-18-01-0193]--[@b53-mmr-18-01-0193]). This implies dual roles for ERK1/2 and PI3K/AKT in tumor progression and the stress response ([@b50-mmr-18-01-0193]). Currently, it has been reported that several downstream targets were regulated by PI3K/AKT, including Forkhead box protein O1, mammalian target of rapamycin and endogenous nitric oxide synthase ([@b54-mmr-18-01-0193]). However, the downstream targets of ERK1/2 and PI3K/AKT are not clear in the present study. Furthermore, the mechanisms of cardiac protection involve a complex signaling cascade, and how ERK1/2 and PI3K/AKT signals crosstalk with other signaling pathways requires further investigation.

In conclusion, the present study identified that ACP decreased mitochondrial dysfunction and improved cell viability of cardiomyocytes treated with Ang II. In addition, ACP decreased hypoxia-induced apoptosis in cardiomyocytes treated with Ang II. Furthermore, ACP inhibited the activation of ERK1/2 and PI3K/AKT signaling pathways. It can be hypothesized that the protective effects of ACP on hypoxia-induced apoptosis may depend on inactivating the ERK1/2 and PI3K/AKT signaling pathways. The results of the present study demonstrated the potential application of ACP and provide important molecular evidence for the clinical treatment of cardiac diseases.
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![Cytotoxicity of ACP on cardiomyocytes. Cell viability was determined using the Cell Counting kit-8 method. \*\*P\<0.01 vs. 0 mg/ml ACP. ACP, *Actinidia chinensis* planch polysaccharide.](MMR-18-01-0193-g00){#f1-mmr-18-01-0193}

![Effects of ACP on Ang-II-induced cardiac hypertrophy. (A) Immunofluorescence staining for cardiac troponin T following treatment with ACP and Ang II. Scale bar, 20 µM. (B) The relative cell area was measured by Image Pro-Plus software. (C) Analysis of protein synthesis rate. (D) Bradford assay for analysis of the relative protein concentration. Data were presented as the mean ± standard deviation (n=3). Ang II (1 µM) and ACP (1.25 mg/ml) treatment was applied. \*P\<0.05 and \*\*P\<0.01 vs. control; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. Ang II. ACP, *Actinidia chinensis* planch polysaccharide; Ang II, angiotensin II; FITC, fluorescein isothiocyanate; DAPI, 4′,6-diamidino-2-phenylindole; CPM, counts per minute.](MMR-18-01-0193-g01){#f2-mmr-18-01-0193}

![ACP maintained the cell survival of cardiomyocytes. (A) Flow cytometry analysis of MMP. (B) Quantitative analysis of flow cytometric data. (C) Cell viability analysis using the Cell Counting kit-8 method. ACP (1.25 and 2.5 mg/ml) pretreatment groups: MGH+1.25, MGH+2.5. Data were presented as the mean ± standard deviation (n=4). \*P\<0.05 and \*\*P\<0.01 vs. CK; ^\#^P\<0.05 vs. MGH. ACP, *Actinidia chinensis* planch polysaccharide; CK, control mock; MG, model group; MGH, hypoxia treatment group; MMP, mitochondrial membrane potential.](MMR-18-01-0193-g02){#f3-mmr-18-01-0193}

![ACP decreased hypoxia-induced apoptosis *in vitro*. (A) Apoptosis of cardiomyocytes was detected by flow cytometric analysis. (B) Determination of cell apoptosis rate. (C) Quantitative analysis of AIF and caspase-3/8/9 mRNA expression. (D) Western blot analysis and (E) quantification of AIF and cleaved caspase-3/8/9. GAPDH was used as the loading control. ACP (1.25 and 2.5 mg/ml) pretreatment groups: (MGH+1.25, MGH+2.5). Data were presented as the mean ± standard deviation (n=4). \*P\<0.05 and \*\*P\<0.01 vs. CK; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. MGH. AIF, Apoptosis-inducing factor mitochondria associated 1; ACP, *Actinidia chinensis* planch polysaccharide; CK, control mock; MG, model group; MGH, hypoxia treatment group; Ang II, angiotensin II.](MMR-18-01-0193-g03){#f4-mmr-18-01-0193}

![ACP inhibited the phosphorylation of ERK1/2 and PI3K/AKT in H9c2 cells. Western blot analysis of (A) p-ERK1/2, (B) p-PIK3 and p-AKT. GAPDH was used as the loading control. (C) Quantitative analysis of western blots. The different ACP pretreatment concentrations of ACP applied were 1.25 and 2.5 mg/ml. Data were presented as the mean ± standard deviation (n=4). \*P\<0.05 and \*\*P\<0.01 vs. control; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. MGH (+Ang II/+Hypoxia/-ACP). ACP, *Actinidia chinensis* planch polysaccharide; MGH, hypoxia treatment group; p, phosphorylated; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; ERK 1/2, extracellular signal-regulated kinase 1/2; Ang II, angiotensin II.](MMR-18-01-0193-g04){#f5-mmr-18-01-0193}

![Activation of ERK1/2 and PI3K/AKT reversed the apoptotic effect of ACP. (A) Flow cytometric analysis for the detection of apoptosis. (B) Quantitative analysis of the rate of apoptosis. The ACP (2.5 mg/ml) pretreatment groups included the following: (MGH+2.5), EGF (100 ng/ml) and ACP (2.5 mg/ml) treatment group (EGF+ MGH+2.5), and the IGF-I (100 ng/ml) and ACP (2.5 mg/ml) treatment group (IGF-I + MGH+2.5). \*P\<0.05 and \*\*P\<0.01 vs. CK; ^\#\#^P\<0.01 vs. MGH; ^++^P\<0.01 vs. MGH+ACP. ACP, *Actinidia chinensis* planch polysaccharide; CK, control mock; MG, model group; MGH, hypoxia treatment group; EGF, epidermal growth factor; IGF-I, insulin-like growth factor 1; Ang II, angiotensin II; PI, propidium iodide; FITC, fluorescein isothiocyanate.](MMR-18-01-0193-g05){#f6-mmr-18-01-0193}
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